Study of TV-1106 in Growth Hormone-Deficient Adults

You may be eligible if

• Inclusion:
• males and females 18 years of age or over
• diagnosis of adult growth hormone deficiency (GHD) for at least 6 months, or patients who have hypopituitarism from surgical resection
• no history of exposure to any rhGH within the past 12 months prior to screening
• stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen, testosterone, vasopressin) for at least 3 months prior to screening
• * Other criteria apply, please contact the investigator for more information
• Exclusion:
• patients with acute or chronic conditions or diseases that could confound results of the study or put the patient at undue risk as determined by the investigator
• Presence of contraindications to rhGH treatment
• patients who have participated in another clinical trial with a new chemical/biological entity within 3 months of screening
• patients with known active malignancy (excluding surgically removed basal cell carcinoma or carcinoma in situ of cervix)
• patients with a previously treated pituitary tumor with evidence of tumor progression in the past year patients with a new diagnosis of pituitary adenoma or other intracranial tumor within 12 months of screening
• presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past 1 year
• patients with type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus as indicated by a glycated hemoglobin (HBA1c) of ≥8%
• patients using weight reducing agents or appetite suppressants
• women who are pregnant or nursing, or planning pregnancy during the study period
• * Other criteria apply, please contact the investigator for more information